AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

Core Insights - AEON Biopharma announced positive initial comparative analytical results for ABP-450, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX [1][3] - The company reported constructive feedback from the FDA following a BPD Type 2a meeting, providing a clear framework for advancing the comparative analytical plan for the ABP-450 biosimilar program [1][2] - AEON strengthened its balance sheet through a $6 million PIPE financing and a note exchange, reducing outstanding debt by more than 90% [1][3] Financial Performance - As of December 31, 2025, AEON reported cash and cash equivalents of $3.0 million, which does not include $4.2 million from the second closing of the PIPE financing in January 2026 [5] - The company incurred a net loss of $39.2 million for the year ended December 31, 2025, compared to a net income of $42.0 million in 2024 [17] Corporate Developments - John Bencich was appointed as Chief Financial Officer, bringing over 25 years of leadership experience in corporate strategy and capital markets [4][10] - AEON plans to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program for ABP-450 [3] Market Context - The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a significant opportunity for biosimilar entry [7] - ABP-450 is manufactured by Daewoong Pharmaceutical in a facility authorized by the FDA, Health Canada, and the European Medicines Agency [7]